At a glance
ClinicalIndex Comparison RecordN/ACompleted· 72 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Measurement of Different Anti-Müllerian Hormone Isoforms in Expected Poor Responders: Does it Matter?
In Brief
An observational study for Anti-Mullerian Hormone Isoforms. Completed, enrolled 72 participants across 1 site.
Detailed Summary
This study wants to evaluate significant clinical impact of different AMH isoforms in serum can be present or absent in expected poor responder participants. The specific AMH isoforms could therefore be measured in expected poor responder participants in order to obtain a more realistic clinical picture and therefore be able to give proper information to the participants and selection of medication dose for ovarian stimulation.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsAnti-Mullerian Hormone Isoforms
CountriesUnited Arab Emirates
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
First PostedFeb 2019
Enrollment StartFeb 2019
Primary CompletionDec 2021
Study CompletionMay 2022
TodayJul 2026
First PostedFeb 1, 2019
Enrollment StartFeb 25, 2019
Primary CompletionDec 23, 2021
Study CompletionMay 30, 2022
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 7.4 years ago